Oral Semaglutide: What the Tablet Costs Against the Pen

Semaglutide is no longer only an injection, and the tablet is the cheapest branded route to it that Novo Nordisk publishes. Before pricing them against each other, though, you have to untangle which tablet is which — because there are now three, and their milligram numbers do not mean the same thing.

Three oral semaglutides, and a milligram trap

Wegovy® tablets — 1.5 mg, 4 mg, 9 mg and 25 mg. Indicated for cardiovascular risk reduction in adults with established CV disease and obesity or overweight, and for weight reduction and long-term maintenance in adults. The label starts the tablet at 1.5 mg once daily for 30 days, titrating every 30 days, with a recommended maintenance dosage of 25 mg once daily.¹

Ozempic® tablets — 1.5 mg, 4 mg and 9 mg. Indicated for glycaemic control in adults with type 2 diabetes and for cardiovascular risk reduction in that population.²

Rybelsus® — 3 mg, 7 mg and 14 mg. Same two indications as the Ozempic tablet, different strengths.²

The two type 2 diabetes tablets share a single FDA label, and it carries an explicit warning: "RYBELSUS and OZEMPIC tablets are not substitutable on a mg-to-mg basis."² A milligram of one is not a milligram of the other. Nothing on any of these labels invites you to convert between a tablet strength and a pen strength either — the Wegovy label's limitation of use says only that concomitant use of the tablets with the injection, or with any other GLP-1 receptor agonist, is not recommended.¹

What Novo charges for each

Self-pay, from Novo's own price guides³:

Wegovy tablet — 1.5 mg $149/mo · 4 mg $149 until 31 August 2026, then $199 · 9 mg $299 · 25 mg $299. Month = one bottle of 30 tablets.

Wegovy pen — $199/mo for a new patient's first two fills at 0.25 and 0.5 mg, then $349 at 0.25 through 2.4 mg. Wegovy HD 7.2 mg $399. Month = one box of four pens.

Ozempic tablet — 1.5 mg $149 · 4 mg $199 · 9 mg $299.⁴

Ozempic pen — $199 for two fills, then $349 at 0.25, 0.5 and 1 mg, $499 at 2 mg.⁴

A year, and why 30 days beats 28

The tablet's month is 30 days. The pen's month is 28. That difference compounds twice: fewer fills a year, and each fill covers more days.

Wegovy tablet, first twelve fills up the label's ladder: $149 + $199 + (10 × $299) = $3,338.

Wegovy pen, thirteen four-weekly fills: (2 × $199) + (11 × $349) = $4,237.

Gap in year one: $899.

At steady state the per-day arithmetic is cleaner still. The tablet at maintenance is $299 ÷ 30 = $9.97 a day. The pen at $349 ÷ 28 = $12.46 a day. The pen costs 25% more per day of treatment, which over 365 days is $3,639 against $4,549 — a $910 difference with no introductory pricing on either side.

The tablet does not cost a pharmacy less

Here is where the story stops being about manufacturing. CMS's NADAC survey reports what retail pharmacies pay wholesalers. On the file dated 5 August 2026, rates effective 22 July⁵:

Wegovy 25 mg tablet — $43.38349 each × 30 = $1,301.50 for a 30-day bottle.

Wegovy 1.5 mg tablet — $43.50931 × 30 = $1,305.28.

Wegovy 2.4 mg pen — $435.57294 per mL × 0.75 mL × 4 pens = $1,306.72 for a 28-day box.

Five dollars and twenty-two cents separate the cheapest of those from the dearest. The same holds on the diabetes side: the Ozempic 1.5 mg tablet is $992.72 for 30 days and the Ozempic 2 mg pen is $995.81 for 28.

So the tablet is not cheaper to acquire. It is cheaper to buy, by $900 a year, because Novo priced it that way. That is a perfectly legitimate commercial choice — and it is also the sort of thing worth knowing before you assume the cheaper form is the lesser product.

One of the three is being retired

A query against FDA's drug shortages data on 7 August 2026 returns Rybelsus 3 mg, 7 mg and 14 mg — all three strengths — with the status "To Be Discontinued", posted on 4 June 2026.⁶

That is a supply-status flag from the manufacturer to FDA, not a safety action and not a recall. But if you are pricing a long-term oral semaglutide plan around Rybelsus specifically, it is the single most relevant fact on this page, and it appeared in a database rather than in a press release.

What the tablet does not carry

Price is not the only column. The Wegovy injection's label carries two indications the Wegovy tablet's does not: weight reduction in patients aged 12 and over, and — under accelerated approval — non-cirrhotic MASH with moderate-to-advanced fibrosis.¹

The tablets also come with administration conditions the pens do not: taken orally once daily on an empty stomach in the morning with no more than four ounces of water, swallowed whole, with at least 30 minutes before food, other drinks or other oral medicines.¹ Whether that fits a life is not a cost question, but it is the reason the cheaper option is not automatically the right one.

What we could not price

We could not price a Wegovy tablet against a Wegovy pen at equivalent exposure, because no first-party source publishes a conversion between the two and the label does not offer one. The comparison above is between two complete twelve-month courses at their published prices, not between two strengths.

We could not find a NADAC line for the Wegovy 9 mg or Ozempic 9 mg tablet at the 22 July effective date under a description we could verify, so those tiers appear here at their retail price only.

And we could not price either form through insurance, because plan-level cost sharing is not published per drug.

For the pen against the other manufacturer's pen, see Zepbound vs Wegovy. For the full Novo price sheet including the Medicare route, see what NovoCare Pharmacy costs. For the compounded oral products sold as an alternative, see the compounded semaglutide board and our Strut Health review.

Wegovy®, Ozempic® and Rybelsus® are registered trademarks of Novo Nordisk A/S.